EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization

Nicolas Bauer iD, Dimitrios-Ilias Balourdas iD, Joel R Schneider, Xin Zhang, Lena M Berger iD, Benedict-Tilman Berger iD, Martin P Schwalm iD, Nick A Klopp, Jens T Siveke, Stefan Knapp iD, Andreas C Joerger iD

ACS Chemical Biology · 2024

DOI: 10.1021/acschembio.3c00427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Biology, 2024. Verfasst von Nicolas Bauer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium f?r Bildung und Forschung, Deutsches Krebsforschungszentrum, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinomaAntineoplastic AgentsHumansHistone Deacetylase InhibitorsNuclear ProteinsTranscription FactorsPharmacophoreCell Line, TumorRNA-Binding ProteinsBromodomain Containing ProteinsCell Cycle Proteins

Substanzen

Histone Deacetylase InhibitorsNuclear ProteinsTranscription FactorsAntineoplastic AgentsHEXIM1 protein, humanRNA-Binding ProteinsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle Proteins

Autor:innen und Institutionen

  • Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.
  • Structural Genomics Consortium (SGC), Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany.
  • Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
  • Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK Partner Site Essen) and German Cancer Research Center, DKFZ, 69120 Heidelberg, Germany.
  • German Translational Cancer Network (DKTK) Site Frankfurt/Mainz, Frankfurt am Main 60438, Germany.

ORCID-Profile: Nicolas Bauer, Dimitrios-Ilias Balourdas, Lena M Berger, Benedict-Tilman Berger, Martin P Schwalm, Stefan Knapp, Andreas C Joerger

Förderung

  • Bundesministerium f?r Bildung und Forschung
  • Deutsches Krebsforschungszentrum
  • Deutsche Forschungsgemeinschaft
  • Frankfurt Cancer Institute

Zitieren

APA

Bauer, N., Balourdas, D. I., Schneider, J. R., Zhang, X., Berger, L. M., Berger, B. T., Schwalm, M. P., Klopp, N. A., Siveke, J. T., Knapp, S., & Joerger, A. C. (2024). Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization. ACS Chemical Biology. https://doi.org/10.1021/acschembio.3c00427

Vancouver

Bauer N, Balourdas DI, Schneider JR, Zhang X, Berger LM, Berger BT, et al. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization. ACS Chemical Biology. 2024. doi:10.1021/acschembio.3c00427

BibTeX
@article{Bauer2024,
  author = {Bauer, Nicolas and Balourdas, Dimitrios-Ilias and Schneider, Joel R and Zhang, Xin and Berger, Lena M and Berger, Benedict-Tilman and Schwalm, Martin P and Klopp, Nick A and Siveke, Jens T and Knapp, Stefan and Joerger, Andreas C},
  title = {Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization},
  journal = {ACS Chemical Biology},
  year = {2024},
  doi = {10.1021/acschembio.3c00427}
}
Kostenlos starten →